QualityStocks
  The QualityStocks Daily Newsletter for Monday, August 30th 2010 Blog  |  Video  |  Market Basics  |  Quotes & News  |  Clients  |  Partners  |  About Us  |  Contact Us

Today's Top 3 Investment Newsletters

1.

HotOTC (IFRS)

2.

Nebula Stocks (GBHL)

3.

Stock traders chat (GRYE)


The QualityStocks Daily

Targacept, Inc. (TRGT)

The Street, Greenbackers, OTC Picks, and Small Cap Investor reported earlier on Targacept, Inc. (TRGT), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Targacept, Inc. is a clinical-stage biopharmaceutical company. They discover and develop novel NNR Therapeutics™ for the treatment of central nervous system diseases and disorders. Targacept leverages their scientific leadership and proprietary drug discovery platform Pentad™ to generate novel small molecule product candidates to fuel their pipeline. Founded in 1997, Targacept, Inc. has their headquarters in Winston-Salem, North Carolina. Trading on the NASDAQ Global Market, the Company has collaborations with AstraZeneca and with GlaxoSmithKline.

Their therapeutic focus is central nervous system diseases and disorders. Their therapeutic targets are neuronal nicotinic receptors (NNRs), which are key regulators of the nervous system. NNRs are receptors on nerve cells that act as the "volume knobs" of the nervous system. They are throughout the brain and nervous system and they regulate and normalize brain and nervous system function. They affect memory, attention, mood, pain, inflammation, movement, and cell survival.

The Company's vision to build health and restore independence for patients has support from clinical-stage product candidates in development for major depressive disorder, attention deficit/hyperactivity disorder, Alzheimer's disease and cognitive dysfunction in schizophrenia, as well as multiple preclinical programs.

The Company's product candidates are TC-5214, major depressive disorder; AZD3480 (TC-1734), attention deficit/hyperactivity disorder (ADHD); AZD1446 (TC-6683), Alzheimer's disease; TC-5619, cognitive dysfunction in schizophrenia or one or more other indications characterized by cognitive impairment; and TC-5685, depression/anxiety disorders. For Intellectual Property, Targacept has Pentad™, a proprietary drug discovery platform, and an extensive patent estate covering compounds that act on NNRs.

Targacept has collaboration agreements with AstraZeneca AB for the development and commercialization of TC-5214 as a treatment for major depressive disorders. They also have a strategic alliance with GlaxoSmithKline. This is to discover, develop, and market product candidates that selectively target specified NNR subtypes in specified therapeutic focus areas.

In June, AstraZeneca and Targacept, Inc. announced the enrollment of the first patient in the Phase 3 clinical development program for TC-5214, a nicotinic channel blocker. The Phase 3 program (the Renaissance Program) is designed to support the planned second half of 2012 filing of a new drug application with the U.S. Food and Drug Administration for TC-5214 as an adjunct treatment for major depressive disorder (MDD). This is in patients with an inadequate response to first-line therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin/norephinephrine reuptake inhibitor (SNRI). A Marketing Authorisation Application in Europe is projected for 2014.

On August 3, 2010, Targacept Inc. announced that they signed a licensing deal with Cornerstone Therapeutics Inc. for potential inflammatory condition treatments. The Company said the deal grants Targacept rights to Cornerstone's NNR-based patents and a library of preclinical compounds.

Targacept, Inc. (TRGT) closed Monday’s trading session at $19.69, up 4.40%, on 130,655 volume.

Shrink Nanotechnologies, Inc. (INKN)

FeedBlitz, Penny Stock Advice, Penny Stocks Expert, and OTC tip Reporter reported earlier on Shrink Nanotechnologies, Inc. (INKN), and we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Shrink Nanotechnologies, Inc. is a nanotechnology company developing products and licensing opportunities in the solar energy production, biotechnology research, and development tools and medical diagnostics businesses. The Company bases their products on proprietary material, a pre-stressed plastic called NanoShrink™, and on their patent-pending manufacturing process called the ShrinkChip Manufacturing Solution™. Shrink Nanotechnologies, Inc. trades on the OTC Bulletin Board. They have their corporate headquarters in Carlsbad, California.

NanoShrink™ is the plastic substrate material the Company uses to build all of the products they design, prototype, and manufacture. Their primary NanoShrink™ substrate is made from a pre-stressed polystyrene material. By taking advantage of certain critical inherent characteristics, shrinkable polystyrene, allows for the ultra-rapid direct patterning of complex, even three-dimensional, stacked polystyrene micro and nanostructures.

This includes single and multi-layered metallized structures as well as advanced optoelectronic devices. Because of the unique characteristic of NanoShrink™ to uniformly compress during heating, complex structures can undergo design at the macro-scale level that upon heating, retain the design at the micro or nano-scale.

The Company's patent-pending process involves printing designed and related microstructures on a larger scale on NanoShrink and then uniformly shrinking them down to a nano-scale size. By using their technologies to "print" on a larger scale, and then "shrink" the same features down to the nano-scale, they eliminate the need for clean rooms and other highly complex robotics or tools needed to accomplish this.

Shrink Nanotechnologies, Inc. is a FIGA™ business - bringing together leaders from the worlds of Finance, Industry, Government and Academia to form a for -profit business. The result is Shrink Nanotechnologies and their technology being well received in leading academic journals. These include Nature Medicine™, Lab-on-a-Chip™ and Advanced Materials™. MIT's Technology Review awarded their prestigious TR35 award to the Company's scientific founder, Dr. Michelle Khine.

Dr. Khine developed innovations, which have become the core of what is now Shrink Nanotechnologies. The Company has exclusive patent pending technologies and is developing products and licensing partnerships in three main vertical markets. These include Solar Energy, Medical and Diagnostic Sensors, and Research Tools to advance innovation in some of the most important medical fields.

On August 3, 2010, Shrink Nanotechnologies, Inc. announced the formation a new wholly-owned subsidiary, Shrink Chips LLC. This subsidiary is dedicated to the commercialization of a suite of next-generation biotechnology research tools. This includes their patent-pending ShrinkChip Rapid Prototyping System (RPS) used to inexpensively and flexibly manufacture microfluidic chips, or Lab-on-a-Chip (LOC), devices as well as many other biological and chemical sensors.

Mark L. Baum, CEO of Shrink Nanotechnologies, Inc. said, “Since our scientific founder, Dr. Michelle Khine, began to receive attention for her novel method of creating low cost microfluidic, biosensing and chemical sensing devices, Shrink has accumulated interest for a commercial system based on Dr. Khine’s ideas. Now that we are getting closer and closer to bringing Dr. Khine’s ideas to the market, we have formed ShrinkChips and will have a focused team working on this project, with a specific mission and the resources to pursue the commercial development of the ShrinkChip Rapid Prototyping System, ultimately accelerating the time-to-market for several new bioscience products.”

Shrink Nanotechnologies, Inc. (INKN) closed Monday’s trading session at $0.0601, up 1.69%, on 65,735 volume with 9 trades. The stock’s average daily volume over the past 60 days is 65,649 with a 52-week low/high of $0.07/$0.84.

Agria Corporation (GRO)

China Vesting and SmallCap Voice reported earlier on Agria Corporation (GRO), and we highlight the Company, here at the QualityStocks Daily Newsletter.

Agria Corporation is a China-based agriculture company with investments in key agriculture markets of China and New Zealand. The Company’s operations in China engage in research and development, production and sale of upstream agriculture products in three categories -- seeds, sheep products and seedlings. Founded in 2000, Agria Corporation trades on the NYSE and they have their headquarters in Beijing, China. They also have an office in Shenzhen, and production bases in Shanxi and other provinces.

The Company processes and packages corn seed products and sell them to local and regional distributors. Their sheep products include frozen semen, embryos, sheep, breeder sheep, and Primalights III hybrid sheep. These are primarily for government-operated breed improvement and reproductive stations, breeding companies, and other sheep reproductive stations and farms.

Agria Corporation’s seedling products comprise dates and white bark pine seedlings to end users. The Company has a strategic co-operation framework agreement with the China National Academy of Agricultural Sciences. This agreement provides for future co-operation across the spectrum of agricultural research.

In March of this year, Agria Corporation announced the appointment of a pre-eminent China corporate strategist Kenneth J. DeWoskin, Ph.D., as an independent director of the Company. They also provided an update on the Company's ongoing strategic review. Dr. DeWoskin is a well regarded and regular presenter on China business issues throughout the U.S., Europe and Asia including at the World Economic Forum. He has lived and worked extensively in both China and in Japan over the past 45 years.

In addition, Mr Xie Tao, the CEO of Agria, was appointed a director of the Company and will serve on the Corporate Governance and Nominating Committee of Agria. Mr. Alan Lai, Agria's Chairman, now serve as the Chairman of their Compensation Committee.

Agria is working to grow a focused seed business in China. Agria believes that the PRC government and the agricultural industry participants share the same goal of improving agricultural productivity, evidenced by strong foreign and domestic investment flowing into the agricultural industry in China. Agria considers that focusing on the seed sector will best position it to achieve sustainable growth in the future.

On July 13, 2010, Agria Corporation announced that they entered into definitive agreements to divest Taiyuan Primalights III Agriculture Development Co., Ltd., or P3A, to Mr. Frank Xue, the president and a director of P3A, in line with the agreement in principle announced by Agria on June 29, 2010. The leases over nine parcels of land totaling approximately 13,500 acres previously held by P3A have been retained by the Agria group.

Agria Corporation (GRO) closed Monday’s trading session at $1.52, up 7.80%, on 54,885 volume with 76 trades. The stock’s average daily volume over the past 60 days is 114,075 with a 52-week low/high of $1.11/$4.53.

Advanced Battery Technologies, Inc. (ABAT)

Wall Street Resources, China Vesting, SmallCap Voice, and Greenbackers reported earlier on Advanced Battery Technologies, Inc. (ABAT), and we highlight the Company, here at the QualityStocks Daily Newsletter.

Advanced Battery Technologies, Inc. (ABAT) develops, manufactures and distributes rechargeable Polymer Lithium-Ion (PLI) batteries. Founded in September 2002, the Company's products include rechargeable PLI batteries for electric automobiles, motorcycles, mine-use lamps, notebook computers, walkie-talkies, and other electronic devices. Advanced Battery Technologies, Inc. trades on the NASDAQ Capital Market. They have a New York office, with their executive offices and manufacturing facilities in China.

On April 28, 2009, the Company, through Cashtech, a wholly owned subsidiary of ABAT, entered into a Share Purchase Agreement with the shareholders of Wuxi Angell Autocycle Co., Ltd. The Company acquired a 100 percent ownership interest in the registered capital of Wuxi Angell and issued three million shares of the Company's common stock to the sellers. Immediately after the completion of acquisition on May 4, 2009, Wuxi Angell Autocycle Co. Ltd. renamed as Wuxi Zhongqiang Autocycle Co., Ltd. In June and October 2009, in order to support the future growth of their newly acquired electric vehicle business and battery production, the Company completed additional equity placements.

ABAT's batteries combine high-energy chemistry with state-of-the-art polymer technology to overcome many of the shortcomings associated with other types of rechargeable batteries. Wuxi Zhongqiang Autocycle Co., Ltd, founded in 2002, develops and manufactures various types of electric vehicles. Wuxi Zhongqiang owns three types of products listed in the E-Bike directory, with more than 20 varieties. These include electric bikes; agricultural transport vehicles for practical transportation; sport utility e-vehicles such as scooters, off-road vehicles, go-karts, snow scooters, sea scooters, as well as underwater propeller vehicles. Wuxi Zhongqiang products export to countries and regions in Europe, as well as the United States and Asia.

On August 26, 2010, Advanced Battery Technologies, Inc. announced that on August 24, 2010 they signed a polymer lithium-ion phosphate battery supply contract with Hengmin Opto-electrical Tech Co., based in DongGuan City, Guangdong Province. Hengmin primarily engages in lithium-battery pack assembly and power management systems production and sales. The Company will deliver lithium-ion phosphate battery packs, which provide the power source for LED lights, walkie-talkies and street lamps.

Mr. Zhiguo Fu, Chairman and CEO of Advanced Battery Technologies, Inc., stated, "We are pleased about this new battery order. Hengmin has researched the market and compared our batteries with competitors and their order is a further validation of the quality and value of our Company's polymer lithium-ion batteries. We view this contract as a confirmation of our commitment to research and development and we will continue our efforts of providing the most updated and advanced technology for our customers."

Advanced Battery Technologies, Inc. (ABAT) closed Monday’s trading session at $3.59, down 1.64%, on 820,103 volume with 2,586 trades. The stock’s average daily volume over the past 60 days is 494,142 with a 52-week low/high of $3.02/$4.80.

GoSolarUSA Inc. (GSLO)

Stock Fortune Teller reported today on GoSolarUSA Inc. (GSLO), StockEgg, Hot OTC, Bull Rally, Stock Source, Penny Invest, Cool Penny Stocks, Stock Rich, PennyTrader Publisher, and OTC Picks did last week, and we highlight the Company as “One to Watch” this week, here at the QualityStocks Daily Newsletter.

GoSolarUSA Inc. is focused on identifying, developing and manufacturing new solar energy technologies in the United States. They are working to advance clean American solar technology to compete in an industry sector that includes such companies as First Solar, Inc. (NASDAQ: FSLR). GoSolarUSA Inc. has their headquarters in New Orleans, Louisiana.

GoSolarUSA Inc.’s President, Tyson Rohde, has years of investment banking and business development experience. He has served as the Chief Operating Officer and a director for Southfield Energy Corporation, assisting with the origination and management of oil and gas investments. Mr. Rohde was also the Chief Executive Officer and director of Biotricity Corporation from December 2008 to 2010. There, he oversaw technological and business development activities.

On August 17, 2010, GoSolarUSA Inc. disclosed that they have scheduled initial tests to verify design parameters of the newly acquired “Solar Forced Air Furnace” technology (Patent Pending). They plan to initiate testing of Solar Furnace components next month, with additional testing expected to continue over the course of several months.

The design of initial tests will be to measure total heat transfer from solar tubes to specified volumes of air flow. Results from these tests will then be used to calibrate the system for design coordination with existing forced air heating systems.

Forced air heating systems are used in 35 Million homes in the United Sates. The Company’s new Solar Forced Air Furnace design will be to easily adapt to existing systems in these 35 Million homes to reduce heating costs and provide a low-cost, “green” energy source.

On August 27, 2010, GoSolarUSA announced that their management signed another groundbreaking deal with PREE Corp. to configure their proprietary PREEcharge technology for use with the iPAD and Kindle.

The PREEcharge technology captures electrons from WLAN and Bluetooth waves and converts them into power to recharge batteries for wireless devices. The technology also incorporates a small solar panel to augment the charge with solar energy. So far, the entire product development has focused on configuration for use with smaller wireless devices. With the funding from GoSolarUSA, PREE will be able to accelerate the development of the PREEcharge for use with wireless PC tablets.

“I was blown away by the potential of this new technology,” stated Tyson Rohde, President of GoSolarUSA. “The engineers and business development team at PREE are doing something profound, and I think people will understand its value fast.”

We have GoSolarUSA Inc. (GSLO) locked on our radar screens as “One to Watch”, this week, here at the QualityStocks Daily Newsletter.

GoSolarUSA Inc. (GSLO) closed Monday’s trading session at $0.65, up 14.04%, on 1,046,301 volume with 350 trades. The stock’s average daily volume over the past 60 days is 196,524 with a 52-week low/high of $0.05/$2.25

PureSafe Water Systems, Inc. (PSWS)

Microcap Voice and Investors Underground reported earlier on PureSafe Water Systems, Inc. (PSWS), and we highlight the Company, here at the QualityStocks Daily Newsletter.

Trading on the OTCBB, PureSafe Water Systems, Inc. develops advanced mobile water purification systems for disaster relief. The Company's commitment is to becoming a worldwide pioneer in disaster relief solutions. Formerly known as Water Chef, Inc., the Company changed their name to PureSafe Water Systems Inc. in November 2008. PureSafe Water Systems Inc. has their headquarters in Plainview, New York.

The Company developed the PureSafe™ patented technology and innovative line of mobile water purification systems. They especially designed their mobile units for rapid deployment in disaster areas across the U. S. and globally. PureSafe™ bottled purified water exceeds the stringent potable water quality standards of the Environment Protection Agency (EPA) and the World Health Organization (WHO).

In addition to disaster relief, PureSafe ™ systems can be further customized and used in a wide range of applications. Examples include remote communities, armed forces, mobile medical facilities, mining companies, municipalities, residential buildings, hotels and other densely populated areas.

PureSafe™ systems provide superior quality desalination and water purification alongside versatile water bottling competencies. The systems undergo installation in a lightweight trailer with uplifting capability by helicopter for instant deployment in any disaster zone. This is to provide the affected population with purified bottled drinking water on site and for the duration of the identified need.

The design of their First Response Water System (FRWS) is specifically to meet on-site clean drinking water needs by First Responders and local citizens during natural and man-made disasters. Their FRWS can deliver up to 30,000 gallons per day of fresh, EPA-compliant water from "any source at any time" within 30 minutes of reaching, by land or by helicopter, the affected scene. It can provide clean potable water for up to 45,000 people a day.

On June 14, 2010, Leslie J. Kessler, Chairman and CEO of PureSafe Water Systems, Inc. announced that the Company entered into a project agreement with Underwriters Laboratories (UL) to evaluate the PureSafe™ First Response Water System for electrical safety and water purification performance. PureSafe™ chose UL because of their respected reputation as one of the world’s leading third-party testing and certification organizations for safety and performance evaluations.

PureSafe Water Systems, Inc. (PSWS) closed Monday’s trading session at $0.1150, up 9.52%, on 203,286 volume with 31 trades. The stock’s average daily volume over the past 60 days is 249,094 with a 52-week low/high of $0.0379/$0.29.

Kria Resources (KIA.V)

We are highlighting Kria Resources (KIA.V), here at the QualityStocks Daily Newsletter.

Kria Resources is a base metal exploration and development company. Their corporate focus is on high quality, advanced-stage base metal assets. Their primary asset is the Halfmile Lake and Stratmat properties near Bathurst, New Brunswick. Founded in 2006, Kria Resources has their headquarters in Toronto, Ontario. They trade on the TSX Venture Exchange.

The Company's Halfmile Lake property has a NI 43-101 compliant Indicated mineral resource estimate of 6.26 million tonnes grading 8.13 percent zinc, 2.58 percent lead, 0.22 percent copper and 30.78 g/t silver using a 5.0 percent capped zinc equivalent cut-off grade. They have an Inferred resource estimate of 6.08 million tonnes grading 6.69 percent zinc, 1.83 percent lead, 0.14 percent copper and 20.51 g/t silver using a 5.0 percent capped zinc equivalent cut-off grade.

Their Stratmat property has an Inferred Mineral Resource estimate of 5.52 million tonnes grading 6.11 percent zinc, 2.59 percent lead, 0.40 percent copper and 54.21 g/t silver using a 5.0 percent zinc equivalent cut-off grade. The Company also has the Ruttan copper-zinc sulphide project near Leaf Rapids, Manitoba. This project has an NI 43-101 compliant mineral inferred resource estimate of 19.75 million tonnes grading 1.17 percent copper and 1.47 percent zinc using a 1.0 percent capped copper equivalent cut-off grade.

Kria Resources also has the Ruttan copper-zinc sulphide project near Leaf Rapids, Manitoba. It has an NI 43-101 compliant mineral inferred resource estimate of 19.75 million tonnes grading 1.17 percent copper and 1.47 percent zinc using a 1.0 percent capped copper equivalent cut-off grade.

Kria has been in discussions with Xstrata Zinc to examine the potential of utilizing Xstrata's Brunswick 12 mill to toll process ore from Kria's Halfmile Lake property once it advances to production. Xstrata Zinc's Brunswick mill, located outside Bathurst, New Brunswick, is approximately 40 kilometers from Kria's Halfmile Lake property.

Supplying supplemental ore from Kria's Halfmile Lake property to the Xstrata mill would allow Kria to speed up their timeline to commencing production. It will allow for a phased approach to further development of the mine and processing facilities. Kria intends, upon receipt of governmental permits, to begin development activities at the Halfmile site in order to begin supplying ore to Xstrata's Brunswick processing facility by early 2011.

Kria Resources (KIA.V) closed Monday’s trading session at $0.1450, up 7.41%, on 207,750 volume.

China TransInfo Technology Corp. (CTFO)

Greenbackers reported recently on China TransInfo Technology Corp. (CTFO), China Vesting, and Small Cap Network did earlier, and we highlight the Company, here at the QualityStocks Daily Newsletter.

Founded in 2000, China TransInfo Technology Corp. is a provider of public transportation information systems technology and comprehensive solutions in China. The Company engages in developing multiple applications in transportation, digital city, land and resource filling systems based on Geographic Information Systems (GIS) technologies. The use of these is to service the public sector. China TransInfo Technology Corp. trades on the NASDAQ Global Market. They have their headquarters in Beijing, China.

The Company aims to become the largest transportation information products and comprehensive solutions provider. They also aim to be the largest real time transportation-information platform operator and provider in China. The Company provides their services and solutions through their affiliate, China TransInfo Technology Group Co., Ltd., (the Group Company) and the Group Company's PRC operating subsidiaries.

China TransInfo Technology Corp. is developing their transportation system to include Electronic Toll Collection (ETC) technology. They are a co-formulator of several transportation technology national standards. The Company owns software copyrights for 89 software products. They have won 5 of the 10 model cases sponsored by the PRC Ministry of Communications. China TransInfo won their first ETC project in Zhejiang Province in 2009. They then proceeded to win bids in Jiangsu, Shandong, Shaaxi Shanxi provinces and Tianjin Municipality.

Their affiliation with Peking University provides the Company access to the University's GeoGIS Research Laboratory. China TransInfo Technology Corp. is playing a key role in setting the standards for electronic transportation information solutions.

Today, China TransInfo Technology Corp. announced that the Company was recently awarded electronic toll collection (ETC) contracts totaling RMB 44.6 million (approximately $6.7 million) in Shanxi Province, Shandong Province and Sichuan Province. They will provide ETC electronics engineering machinery systems, ETC application system development and upgrading services, and 10,000 onboard electronic tags for highway authorities in Shanxi Province. They will also provide 10,000 onboard electronic tags and 120 readers for highway authorities in Shandong Province and Sichuan Province.

China TransInfo Technology Corp. (CTFO) closed Monday’s trading session at $6.47, down 0.31%, on 79,395 volume with 363 trades. The stock’s average daily volume over the past 60 days is 156,971 with a 52-week low/high of $5.00/$17.29.

The QualityStocks Company Corner

Uranium Energy Corp. (UEC)

The QualityStocks Daily Newsletter would like to spotlight Uranium Energy Corp. (UEC) Today, Uranium Energy Corp. closed trading at $2.53 on 312,045 volume with 1,011 trades. The stock’s average daily volume over the past 60 days is 361,727 with a 52-week low/high of $2.11/$4.16.

Uranium Energy Corp. (UEC) announced that the Company has completed the first of three phases of wellfield development at Production Area One ("PAA-1") at the Palangana ISR uranium project located in South Texas.

Uranium Energy Corp. (UEC) is a U.S.-based exploration and development company focused on near-term uranium production in the U.S. The company’s operations are managed by professionals who have earned a reputable profile through many decades of hands-on experience in the key facets of uranium exploration, development and mining.

Uranium Energy controls one of the largest databases of historic uranium exploration and development in the nation. Using this knowledge base, the company has acquired and is advancing exploration properties of merit throughout the southwestern U.S., a region known as being the most concentrated area for uranium mining in the United States.

The Company’s fully licensed and permitted Hobson processing facility is central to all of its projects in South Texas. Well financed to execute on its key programs, Uranium Energy's Palangana is-situ recovery project is fully permitted, and its Goliad in-situ recovery project is in the final stages of mine permitting for production.

The company’s strategy of acquiring exploration databases and leveraging those databases to generate acquisition targets has proven to be effective thus far. With plans to continue aggressively pursuing this strategy, Uranium Energy Corp is well positioned to capitalize on the world’s first significant alternative energy boom. Disclaimer

Uranium Energy Corp. Blog

Uranium Energy Corp. News:

Uranium Energy Corp Issues Mid-Year Shareholder Report

Uranium Energy Corp Announces Results of AGM

Uranium Energy Corp Announces Historical Resource of 1.5 Million Pounds eU3O8 at the Company's Salvo Project in South Texas

VizStar, Inc. (VIZS)

The QualityStocks Daily Newsletter would like to spotlight VizStar, Inc. (VIZS) Today, VizStar, Inc. closed trading at $0.28, for no change, on 10,335 volume with 4 trades. The stock’s average daily volume over the past 60 days is 60,791 with a 52-week low/high of $0.0162/$0.65.

VizStar, Inc. (VIZS) DBA Celestial Jets, is a premier aviation charter broker focused on delivering a new and unparalleled way to experience private jet travel. The company delivers this unmatched service without monthly membership fees, initiation fees, long term commitments or capital investment, while delivering typical savings of 20-30% when compared to other charter or fractional companies in the market place.

Within as little as four hours notice, Celestial Jets can make all the travel arrangements for their client's next trip. Whether it is a short hop or an intercontinental journey, business or pleasure, each and every detail is attended according to the client's specific requirements. With access to nearly 6,000 qualified aircraft, ranging from light, mid, heavy or jumbo jets, Celestial Jets is capable of serving any potential client.

The company adheres to the highest and most up-to-date safety standards of today. Each aircraft, in correspondence with FAA law, is flown by two pilots, each with outstanding credentials and type rated for the aircraft they are flying. Celestial Jets also abides by the strict protocol of the Transportation Security Administration, the Federal Bureau of Investigation and all other federal and local law enforcement agencies.

Celestial Jets' service goes much further than just the flight, offering chauffeured limousine pickup with planeside drop off, world class catering, hotel and resort accommodations, and restaurant reservations, in addition to technical support, accounting, legal, or secretarial services, spa treatments, event planning, and childcare. Leaving no detail to chance or any expectation left unmet, Celestial Jets takes care of everything at the most competitive prices in the industry. Disclaimer

VizStar, Inc. Blog

VizStar, Inc. News:

VizStar, Inc. Opens Strategically Significant Office in Los Angeles, California

VizStar, Inc. President and CEO Highlighted as a Featured Guest on Mind Your Own Business (MYOB) Radio Show

UPDATE VizStar, Inc. Appoints Aviation Expert Thomas Tamulinas as Director of Flight Operations

Cellceutix Corp. (CTIX)

The QualityStocks Daily Newsletter would like to spotlight would like to spotlight Cellceutix Corp. (CTIX). Today, Cellceutix Corp. closed trading at $0.45, for no change, on 5,000 volume with 1 trade. The stock’s average daily volume over the past 60 days is 3,203 with a 52-week low/high of $0.23/$1.01.

Cellceutix Corporation (CTIX) an emerging bio-pharmaceutical company, is in the early stages of receiving an influx of media attention and widespread notoriety within the pharmaceutical industry due to the promising results shown during the early development of a compound for the treatment of autism, KM-391, and the approaching Phase 1 clinical trials of Kevetrin™, the company's compound for the treatment of drug-resistant cancers. In addition to these two, Cellceutix currently manages a portfolio of six other promising compounds.

KM-391, a 100% novel compound, is revolutionary in that it addresses the core issues of autism, unlike the pharmaceuticals presently on the market which merely treat the symptoms that result from autism. Preliminary testing of KM-391 revealed that test animals showed a significant increase in serotonin uptake compared to controls with noticeable and measurable positive therapeutic changes. Cellceutix is rapidly developing KM-391 in response to the public outcries received by the company since the results of early testing had been made publicly available.

Kevetrin, Cellceutix's flagship product, is nearing Phase 1 clinical trials on humans with FDA regulated pre-clinical testing completed and the data being properly compiled for the IND application. While most cancer treatments today are derivatives of other compounds, Kevetrin is completely unique. Multidrug resistance, the principal mechanism by which strains of cancer develop resistance to chemotherapy drugs, is a major factor in the failure of many forms of chemotherapy today and represents a huge need for novel cancer treatments.

Kevetrin has been extensively studied in animal models of lung, breast, and colon cancers, targeting carcinoma strains that have proven resistant to standard therapies available on the market today with the results showing greater tumor growth delay than present therapies and strong efficacy in mouse models with increasing dosages. A successful drug for the treatment of drug-resistant cancers is purported to generate billions of dollars in annual revenues.

The Company has procured leading figures in the health and science arenas to lead its development efforts. The officers and advisors of Cellceutix include pioneers in the fields of cancer and genetics, as well as those who have been integral to mergers, acquisitions and the generation of exorbitant revenues through ground breaking therapies while holding high-level executive and research positions at industry giants such as Pfizer and Eli Lilly. Holding over a century of highly relevant experience in the pharmaceuticals industry, the team has been assembled with the specific goal of duplicating these past successes while revolutionizing much needed treatments for today's most challenging diseases. Disclaimer

Cellceutix Corp. Blog

Cellceutix Corp. News:

Cellceutix Completes All Three Animal Safety Pharmacology Studies for Its Cancer Compound Required by FDA Prior to Filing Investigational New Drug (IND) Application

AllPennyStocks.com News: Drug-Resistant Cancers Now a Focal Point for Progressive Biotechs

AllPennyStocks.com Announces Corporate Write-Up on Cellceutix Corp. (OTCBB:CTIX)

Micro Identification Technologies Inc. (MMTC)

The QualityStocks Daily Newsletter would like to spotlight Micro Identification Technologies Inc. (MMTC) Today Micro Identification Technologies Inc. closed trading at $0.0230, down 4.17%, on 218,180 volume with 18 trades. The stock’s average daily volume over the past 60 days is 195,786 with a 52-week low/high of $0.02/$0.138.

Micro Identification Technologies Inc. (MMTC) is focused on becoming a global leader in developing, supporting and marketing rapid systems and processes that detect and identify microbial organisms. For several years the company has been working on the development of a breakthrough, laser-based microbial identification technology. This technology has been designed to be extremely fast and easy to use while not relying on conventional chemical or biological processing, fluorescent tags, gas chromatography or DNA analysis.

The system works by measuring scattered light intensity as individual microbes pass through a laser beam. The intensity pattern of the scattered light is a direct consequence of the size, shape and external and internal optical characteristics of the microbe. By measuring scattered light at specific angles, MIT’s system detects and differentiates objects the size of bacteria, protozoa, yeasts and molds.

The company’s technology offers significant advantages over today’s methods of microbial detection, including lower cost, rapid results, easier use and the ability to test for multiple bacteria in one process. The system is statistically based and includes a unique MIT Microbe Library of pre-measured light scattering identifiers - or fingerprints - derived from the measurements of tens of thousands of individual microbes for each species and subspecies to be detected.

MIT’s technology has the potential to revolutionize the $5 billion rapid microbial test market by annually saving thousands of lives and tens of millions of dollars. Since 1998, the industry has had an annual expansion of 9.2 percent - with growth projections for 30 percent annually. MIT is well positioned with its cutting-edge microbial technology as demand continues to soar as a result of major health, safety and homeland security issues. Disclaimer

Micro Identification Technologies Inc. Blog

Micro Identification Technologies Inc. News:

MIT Initiates Expansion Plans Enabled by Recently Completed Manufacturing and Financing Agreements

MIT Contracts OSI Optoelectronics to Manufacture the MIT 1000 Rapid Microbial Identification System

U.S. Equity News Features Micro Identification Technologies in the Fight Against Bacteria

China Pharmaceuticals Inc. (CFMI) Posts Record Q2 Financials

China Pharmaceuticals Inc., a leading manufacturer and distributor of prescription and over-the-counter pharmaceuticals, today announced record financial results for its second quarter ended June 30, 2010.
The company reported total revenue for the quarter of $10.44 million, up 105 percent from $5.08 million reported for the second quarter of 2009.
Gross profit increased 89 percent to $6.08 million, up from $3.21 million reported for the comparable period of last year.

Operating income grew 204 percent to $6.35 million as compared to $2.08 million reported for the second quarter ended June 30, 2009.
China Pharmaceuticals’ net income increased 208 percent to $5.37 million, or diluted earnings per share of $0.16, as compared to 2009 second-quarter net income of $1.74 million, or diluted earnings per share of $0.06.

“We are extremely delighted to report a strong second quarter of 2010, with revenues and net income significantly exceeding our expectations. We continue to believe that the factors that contributed to this performance were strong sales from our new products and the highly effective restructuring of our sales and marketing network. …,” stated Guozhu Wang, chairman and CEO of China Pharmaceuticals stated in the press release. “We are focused on continuing to expand our portfolio of high margin products and aggressively expanding our sales and marketing network that will allow us to continue to build sustainable growth in revenues and profits.”

As of June 30, 2010, the company had $6.73 million in cash. Working capital increased 94 percent to $17.94 million, up from $9.24 million as of December 31, 2009. Long-term debt remains at Nil. Shareholders’ equity as of June 30, 2010 was $36.88 million, as compared to $28.62 million at the end of December 31, 2009. Total assets as of June 30, 2010 amounted to $40.13 million.

China Pharmaceuticals also noted its optimism for the remainder of fiscal 2010, saying that it expects continued growth and expansion.
“Fiscal 2010 continues to be a transitional year for China Pharmaceuticals as we prepare for the introduction of new drugs, and pursue additional opportunities for both organic growth and potential strategic acquisitions.

Our current outlook reflects only the drugs that we have in hand today and will be subject to update as we execute strategic initiatives to expand our market position and profitability in the future. Based on our performance to date, we continue to remain extremely optimistic regarding our future growth prospects and look forward to sharing further details with our shareholders as we proceed with our expansion plans,” Guozhu Wang stated.

Uranium Energy Corp. (UEC) Announces Completion of First Phase of Wellfield Development at Palangana in South Texas

Uranium Energy Corp. was pleased to announce this morning that it has completed the first of three phases of wellfield development at Production Area One (“PAA-1″) at the Palangana ISR uranium project located in South Texas.

According to the press release, Uranium Energy completed 40 injection and production wells thus far, marking the end of Phase One in the development of PAA-1. The wells are to be brought on-stream in three approximately equivalent phases as part of the build-up to initial sustainable levels of production. Construction of Palangana’s ion-exchange satellite facility is also underway with pumps and tanks to be installed during the month of September.

Harry Anthony, Chief Operating Officer, stated, “The development progress at Palangana is on-track, on-schedule and on-budget for initial production starting in November this year. We are continuing the drilling, electrical build-out and wellfield piping, and are pleased with the pace and testing to date.”

Uranium Energy also announced that it has completed drilling and flow-testing the Class 1 non-hazardous waste disposal well, known as WDW 419, that is needed for the Palangana project. WDW 419 is permitted for injection of by-product solutions generated during in-situ recovery of uranium and during restoration of the field. The well was drilled and cased to a depth of 6,950 feet in June and July. It was perforated earlier this month with two perforation intervals.

The well has now been flow-tested using filtered brine at several rates ranging between 42 and 176 gallons per minute at wellhead pressures ranging from 0, or a vacuum, up to 300 pounds per square inch, and was successful from applying just these modest wellhead pressures. WDW 419 is in the top 99 percentile of all Class I uranium wells based on superb flow rates at modest injection pressures.

Samples of Revolutions Medical Corp.’s (RMCP) RevVac Safety Syringe to be Completed and Ready for Distribution

Since acknowledgement of the successful completion of a Pilot Run for new manufacturing design changes to the RevVac Safety Syringe earlier in May, Revolutions Medical has been working closely with a U.S. manufacturer to complete market samples. Sporting the company’s new label, these samples have only eight parts compared to twelve, enabling even better performance at lower cost. Now that the market samples are completed, Revolutions Medical can finalize negotiations with manufacturers and distributors.

“Not only do I think we have the world’s least expensive and best automatic retractable safety syringe, our manufacturing price could even be competitive with standard high quality syringes over time. With the many advantages of our safety syringe; reducing accidental needle stick injuries, reducing the spread of blood borne pathogens, and the savings on sharp’s hazardous disposal, I feel we have an actual replacement of the standard syringe that has been used in the medical workplace for decades,” stated Ron Wheet, CEO, Revolutions Medical Corporation.

Revolutions Medical is a safety medical device and software application company. Its medical products include the RevVac safety syringe (FDA approved), safety blood drawing device and safety IV catheter. Through the software division, the company provides RevColor, RevDisplay and Rev3D. The software suite’s functionality includes sorting of images, color, 3D and automatic segmentation of images.

China Industrial Waste Management, Inc. (CIWT) Increases Capacity via Cooperation Contract

China Industrial Waste Management, www.chinaciwt.com – a full-spectrum waste management firm serving Dalian and much of Liaoning Province, reported that its 90-percent owned subsidiary, Dalian Dongtai Industrial Waste Treatment Co., Ltd., signed a substantial waste management cooperation contract with Dalian Onoda Cement Co. Ltd., the production venture arm of established Japanese cement multinational, Taiheiyo Cement Co. Limited.

This contract follows up on the Letter of Intent between Dongtai and Onoda, signed in November of 2008, which has led to the processing of 3k tons of solid waste as part of a trial run using Onoda’s cement kiln to process the waste.

The contract also stipulates the formation of a joint research team by the two companies which will derive new waste management workflows/technologies from the extant collaboration.

CEO of Dongtai, Mr. Jason Dong, hailed the addition of yet another vital waste treatment method as significantly boosting overall industrial waste processing capacity, citing an immediate 36% (20k tons/year) improvement and an eventual 125-143% jump in five years.

Characterizing cement kiln processing as having a great future, given the size of China’s cement industry, Mr. Jason Dong also cited the vast environmental benefits when combined with resource utilization – benefits evinced by the replacement of large amounts of coal with organic waste products for cement production.

Indeed, inorganic waste (like casting sand) is also used, and the method itself opens the door to other materials, from waste plastics and tires to solvents or oils. An advanced cement production facility like Onoda is the ideal partner for Dongtai to cooperate with in the pursuit of technology which will ultimately potentially lead to increased profitability.

 


Sponsors of the Day

 

The QualityStocks Public Company Sponsor News

Micro Identification Technologies Inc. (MIT) (MMTC) MIT Initiates Expansion Plans Enabled by Recently Completed Manufacturing and Financing Agreements

QualityStocks


 

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

Home | Blog | Video | Market Basics | Media | Partners | Clients | About Us | Contact Us | Disclaimer | Unsubscribe
Copyright 2006-2009 QualityStocks 3370 N. Hayden Rd. Suite 123-591 Scottsdale, AZ 85251 480-374-1336